title: Reduction of Orc6 expression sensitizes human colon cancer cells to 5-fluorouracil and cisplatin.
abstract: Previous studies from our group have shown that the expression levels of Orc6 were highly elevated in colorectal cancer patient specimens and the induction of Orc6 was associated with 5-fluorouracil (5-FU) treatment. The goal of this study was to investigate the molecular and cellular impact of Orc6 in colon cancer. In this study, we use HCT116 (wt-p53) and HCT116 (null-p53) colon cancer cell lines as a model system to investigate the impact of Orc6 on cell proliferation, chemosensitivity and pathways involved with Orc6. We demonstrated that the down regulation of Orc6 sensitizes colon cancer cells to both 5-FU and cisplatin (cis-pt) treatment. Decreased Orc6 expression in HCT-116 (wt-p53) cells by RNA interference triggered cell cycle arrest at G1 phase. Prolonged inhibition of Orc6 expression resulted in multinucleated cells in HCT-116 (wt-p53) cell line. Western immunoblot analysis showed that down regulation of Orc6 induced p21 expression in HCT-116 (wt-p53) cells. The induction of p21 was mediated by increased level of phosphorylated p53 at ser-15. By contrast, there is no elevated expression of p21 in HCT-116 (null-p53) cells. Orc6 down regulation also increased the expression of DNA damaging repair protein GADD45beta and reduced the expression level of JNK1. Orc6 may be a potential novel target for future anti cancer therapeutic development in colon cancer.
authors.affiliation: Cancer Genomics Laboratory, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA.
authors.forename: Elaine J
authors.initials: EJ
authors.lastname: Gavin
authors.forename: Bo
authors.initials: B
authors.lastname: Song
authors.forename: Yuan
authors.initials: Y
authors.lastname: Wang
authors.forename: Yaguang
authors.initials: Y
authors.lastname: Xi
authors.forename: Jingfang
authors.initials: J
authors.lastname: Ju
mesh_terms: D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D002945:Cisplatin / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000096:biosynthesis; D005472:Fluorouracil / Q000494:pharmacology*; D016193:G1 Phase; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53; D006801:Humans; D048055:Mitogen-Activated Protein Kinase 8 / Q000378:metabolism; D051738:Origin Recognition Complex / Q000096:biosynthesis* / Q000502:physiology*; D010766:Phosphorylation; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics
chemical_list: D051738:Origin Recognition Complex; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D050760:Cyclin-Dependent Kinase Inhibitor p27; D048055:Mitogen-Activated Protein Kinase 8; D002945:Cisplatin; D005472:Fluorouracil